Amgen and Generate Biomedicines inked a research partnership to discover and develop protein therapeutics for five clinical targets.

Roche was granted an exclusive, worldwide license to develop and commercialize all IL-6 antagonist antibody technology owned by Eleven Biotherapeutics.